Regulating Compounding Pharmacies: Why An Increased FDA Role Shouldn’t Be Our...
By Patrick O’Leary A friend and I were having a conversation about health policy the other day when he observed that drug regulators like FDA face an impossible task in terms of public expectations: as...
View ArticleMassachusetts’ Ban on “Prescribing and Dispensing” Zohydro: The Arguments For...
By Kate Greenwood Cross-Posted at Health Reform Watch As Kurt Karst reported at FDA Law Blog, here, drug maker Zogenix has filed a Motion for Temporary Restraining Order and Preliminary Injunction...
View ArticleLost-Consortium Damages for Same-Sex Spouses
By Alex Stein Yes, those damages are now available. The Connecticut Supreme Court decision that affirmed their availability, Mueller v. Tepler, — A.3d —- (Conn. 2014), was widely anticipated. Back in...
View ArticleMedical Malpractice in Reproductive-Choice Procedures
By Alex Stein Malpractice suits filed in connection with reproductive-choice procedures often present unique problems. The suit filed by Jami Conner against her former gynecologist, Dr. Bryan Hodges,...
View ArticleMedical Publications as Evidence
By Alex Stein Whether a medical publication – a book or an article – can be used in court as evidence for its truth is determined by the “learned treatise” exception to the hearsay rule. This exception...
View ArticleThe Ill-Designed “Continuous Treatment” Rule for the Health Law of Massachusetts
By Alex Stein Under Massachusetts law, suits alleging medical malpractice in a treatment of a minor patient must be filed “within three years from the date the cause of action accrues.” G.L.c. 231, §...
View ArticleThe Health Equity Failures of Massachusetts’ COVID-19 Reopening Plan
By Charlene Galarneau Massachusetts began Phase III of its reopening plan this week. Reopening unquestionably involves disproportionate risks to the health of some residents relative to others, and the...
View Article